Michael C. Venuti

BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Their BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, their technology drives the selection and development of new drug candidates. they leverage their BioMAP® Systems technology in collaborations to enhance the productivity of their pharmaceutical partners' pipelines to identify promising compounds for therapeutic development. Asterand plc acquired BioSeek on February 18, 2010. Asterand is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. BioSeek's BioMAP® platform and primary human cell based assays are highly complementary to the human tissue-based products and services offered by Asterand. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, Asterand plc is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From their offices in Royston (United Kingdom), San Francisco, California and Detroit, Michigan they have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety.

Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA.

TPG Growth LLC is a Venture Capital firm, a subsidiary of TPG Capital Advisors LLC founded in 2000 by William E. McGlashan and Michael Guthrie. The firm is headquartered in San Francisco, United States with additional office in London, United Kingdom.

NeuroTherapeutics Pharma, Inc. is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system hyper-excitability. It is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action. The firm's proprietary molecules target a novel molecular site that will create a pipeline of potential new treatments for multiple CNS disorders. The company's lead compound, NTP-2014, has exhibited excellent efficacy results in multiple preclinical models of epilepsy, acute and neuropathic pain. NeuroTherapeutics Pharma was founded in 2006 and is headquartered in Chicago, IL.

Celera Group provides molecular diagnostics using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers and to develop diagnostic products based on these markers. These diagnostic products are used to predict disease risk and optimize therapy selection, monitoring and patient outcome. The company was founded in May, 1998 and is located in Rockville, MD